N Novartis
Updates & Highlights
Law360 · 5 days ago
Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says
Bloomberg Law News · 6 days ago
Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight
FirstWord Pharma · 7 days ago
Biopharma bites: Moderna welcomes ex-BMS, Novartis exec, plus heart benefits from COVID-19 shots
Recent Openings
View all 2 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
401(k) Match
Retirement savings
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Novartis?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentPatent Claims On Novartis Unit Drug Invalid, Del. Judge Says
Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says
Law360 · 5 days ago
Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight
Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight
Bloomberg Law News · 6 days ago
Biopharma bites: Moderna welcomes ex-BMS, Novartis exec, plus heart benefits from COVID-19 shots
Biopharma bites: Moderna welcomes ex-BMS, Novartis exec, plus heart benefits from COVID-19 shots
FirstWord Pharma · 7 days ago
Novartis Selects Winter Park for New Radioligand Therapy Manufacturing Facility
Novartis Selects Winter Park for New Radioligand Therapy Manufacturing Facility
Orlando Economic Partnership · 7 days ago
Moderna hires Novartis vet to lead commercial, upsizes role for Hoge as potential launches loom
Moderna hires Novartis vet to lead commercial, upsizes role for Hoge as potential launches loom
Fierce Pharma · 7 days ago
Novartis India launches Pluvicto for prostate cancer treatment
Novartis India launches Pluvicto for prostate cancer treatment
The Hindu · 8 days ago
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Zacks Investment Research · 8 days ago
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
Yahoo Finance · 9 days ago
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Fierce Biotech · 12 days ago
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says
GuruFocus · 12 days ago
Novartis says rare muscle disease drug shows promise in early trial
Novartis says rare muscle disease drug shows promise in early trial
Yahoo · 12 days ago
Muscular dystrophy siRNA from Novartis' buyout of Avidity meets biomarker endpoints
Muscular dystrophy siRNA from Novartis' buyout of Avidity meets biomarker endpoints
FirstWord PHARMA · 12 days ago
Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know
Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know
TradingKey · 12 days ago
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
MedCity News · 12 days ago
Sensorion axes hearing loss program; Novartis’ biomarker data in muscular dystrophy
Sensorion axes hearing loss program; Novartis’ biomarker data in muscular dystrophy
Endpoints News · 12 days ago
Novartis doubles down on molecular glue strategy
Novartis doubles down on molecular glue strategy
statnews.com · 12 days ago
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
Benzinga · 12 days ago
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
Citeline News & Insights · 12 days ago
Novartis gets win for another Avidity muscular dystrophy AOC
Novartis gets win for another Avidity muscular dystrophy AOC
pharmaphorum · 12 days ago
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
European Biotechnology Magazine · 12 days ago